Viracta Therapeutics Inc
NASDAQ:VIRX
Intrinsic Value
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of VIRX.
Fundamental Analysis
Balance Sheet Decomposition
Viracta Therapeutics Inc
| Current Assets | 55m |
| Cash & Short-Term Investments | 53.7m |
| Receivables | 281k |
| Other Current Assets | 992k |
| Non-Current Assets | 1.7m |
| PP&E | 464k |
| Other Non-Current Assets | 1.3m |
| Current Liabilities | 38.4m |
| Accounts Payable | 2.4m |
| Accrued Liabilities | 10.7m |
| Other Current Liabilities | 25.3m |
Earnings Waterfall
Viracta Therapeutics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-50.7m
USD
|
|
Operating Income
|
-50.7m
USD
|
|
Other Expenses
|
-365k
USD
|
|
Net Income
|
-51.1m
USD
|
Free Cash Flow Analysis
Viracta Therapeutics Inc
What is Free Cash Flow?
VIRX Profitability Score
Profitability Due Diligence
Viracta Therapeutics Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
Score
Viracta Therapeutics Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
VIRX Solvency Score
Solvency Due Diligence
Viracta Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
Viracta Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VIRX Price Targets Summary
Viracta Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for VIRX is 7 USD .
Ownership
VIRX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
VIRX Price
Viracta Therapeutics Inc
| Average Annual Return | -54.64% |
| Standard Deviation of Annual Returns | 16.65% |
| Max Drawdown | -99% |
| Market Capitalization | 35.5m USD |
| Shares Outstanding | 38 790 480 |
| Percentage of Shares Shorted | 2.09% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. The company is headquartered in Cardiff-By-The-Sea, California and currently employs 24 full-time employees. The company went IPO on 2005-09-27. The firm is focused on the development of new medicines targeting virus-associated malignancies. The firm conducts clinical trials for its combination product candidate as a therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The firm is conducting three clinical trials for its lead product candidate, Nana-val, in EBV+ lymphomas and solid tumors, including a Phase II registrational trial of Nana-val in EBV+ lymphomas. Its lead product candidate is an all-oral combination of nanatinostat. Its development pipeline also includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510, a preclinical-stage PDK-1 inhibitor. Its novel synthetic lethality approach targets the EBV genome to enable the killing of the tumor cells by inducing the expression of certain viral kinase genes which in-turn activate an antiviral drug.
You don't have any saved screeners yet
